The Food and Drug Administration has reversed its position on an experimental gene therapy from Regenxbio, agreeing to reconsider approval for a deadly rare childhood brain disorder. The agency had rejected the treatment just four months prior. The decision marks a significant shift in the regulatory landscape for the biotech firm.
The therapy targets Hunter syndrome, a devastating neurodegenerative condition that typically claims lives in early childhood. Approval would provide the first treatment option for patients with this specific form of the disease. The FDA's willingness to revisit its stance underscores the high unmet medical need.
Regenxbio's gene therapy was initially turned down amid questions about clinical trial data and manufacturing consistency. The company has since submitted additional information to address the agency's concerns. No specific data from the new submission has been disclosed.
An advisory committee meeting is expected to be convened to review the updated evidence, though a timeline has not been set. If approved, the therapy would compete with other emerging treatments for lysosomal storage disorders. The decision carries significant implications for families desperate for therapeutic options.
Investors responded positively, with Regenxbio shares rising on the news. Analysts caution that the reversal does not guarantee final approval and that rigorous scrutiny will continue.